|
Roche / Bondronat
Metastatic Bone Disease
Metastatic bone disease is the spread of cancerous cells from the original tumour to the bone and generally leads to strong pain and other clinical consequences, such as skeletal related events, e.g. fractures, compression of the spine, and hypercalcaemia. Bone pain is the predominant cause for patients to seek medical care.
Current therapeutic options for patients suffering from bone metastases include: chemotherapy, hormonal therapy, radiotherapy, analgesics for pain management, surgery and the use of bisphosphonates.
About Bondronat
Bondronat (ibandronate) is a third generation, highly potent nitrogen-containing bisphosphonate. Clinical trials with Bondronat demonstrated significant rapid and sustained pain reduction and reduction in skeletal related events throughout a two year study time period. Bondronat is registered in over 50 countries world-wide for the treatment of hypercalcaemia of malignancy with over 500.000 patients treated to date. Unlike existing intravenous bisphosphonates Bondronat has not been associated with an increase of renal toxicity.
Bondronat will be available in small sized 50 mg tablets and vials containing 6 mg for intravenous administration.
If you want to buy retail medicines, please click to Bondronat... |
